Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Dose Escalation Study of CLR 131 in Children and Adolescents With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors

Trial Profile

A Phase 1, Open-Label, Dose Escalation Study of CLR 131 in Children and Adolescents With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jan 2019

At a glance

  • Drugs CLR 1404 I-131 (Primary)
  • Indications Brain cancer; Ewing's sarcoma; Glioma; Hodgkin's disease; Lymphoma; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Cellectar Biosciences
  • Most Recent Events

    • 20 Dec 2018 Planned initiation date changed from 1 Jul 2018 to 1 Jan 2019.
    • 13 Aug 2018 According to a Cellectar Biosciences media release,company has received clearance from the FDA for this trial.
    • 09 Jul 2018 According to a Cellectar Biosciences media release, company currently initiating this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top